The emergence of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable buzz within the medical community. This novel dual GIP and GLP-1 agonist medication suggests to deliver significant improvements in body loss compared to existing therapies. Initial clinical studies have demonstrated substantial reductions in body fat percentag